Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Product-news symbols : INCY save search
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
Published: 2023-03-24 (Crawled : 07:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -2.1%
H: 1.41%
C: -0.72%
update
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Published: 2021-05-17 (Crawled : 12:15) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.18%
H: 1.7%
C: -0.24%
positive results positive results phase 3
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: -1.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.82%
H: 0.28%
C: -0.06%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: -5.61%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: -4.71%
H: 0.33%
C: -2.65%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -2.37%
H: 2.04%
C: -2.95%
financial results results
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -2.08%
treatment therapy cancer growth approval
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
Published: 2021-02-22 (Crawled : 16:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.65%
H: 0.59%
C: -0.12%
disease treatment
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
Published: 2021-02-19 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.58%
H: 0.56%
C: -1.8%
dermatitis atopic dermatitis
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
Published: 2021-01-29 (Crawled : 00:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.31%
H: 1.29%
C: -1.36%
positive treatment growth chmp
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.